Dostarlimab (TSR-042)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Dostarlimab (TSR-042), covering 2022-09-10 to 2022-09-10. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer [Phase 2]